James E. Wagner Cultivation Corporation (“
JWC” or
the “
Company”) (TSX VENTURE: JWCA, OTCQX: JWCAF),
a licensed cannabis cultivator and manufacturer focused on
producing clean, consistent cannabis, today reported the Company’s
interim financial results for the fiscal third quarter ended June
30, 2019. Dollar amounts are in Canadian dollars unless otherwise
noted.
Fiscal Q3 2019 Financial and Operational
Highlights
- Revenue totaled a record $749,000, up 32% sequentially from
$566,000, and compared to $3,500 in Q3 2018.
- Net loss and comprehensive loss declined 87% sequentially and
91% from the same year-ago quarter to $434,000 or $(0.01) per
share.
- Both JWC’s pilot facility (“JWC1”) and phase 1
of its flagship facility (“JWC2”) achieved full
operational capacity and production, with initial sales from JWC2
launched in the current quarter.
- Shipped demonstration equipment to Ascendo Group in South
Africa, representing the first potential international deployment
of the Company’s GrowthSTORM™ Dual Droplet™ System.
- Added 23 new strains to the Company’s dried flower collection,
including its proprietary Wagner GE brand, a uniquely balanced 1:2
THC to CBD strain.
- Received cultivation license from Health Canada for the first
pod of phase 2 in JWC2, a production and distribution complex
totaling approximately 345,000 sf. that will utilize JWC's
proprietary GrowthSTORM cultivation platform and
methodologies.
Management Commentary
“Q3 was a milestone quarter for JWC,” said Company president and
CEO, Nathan Woodworth. “Revenue grew 32% sequentially and we
celebrated our first harvest from our new JWC2 facility, allowing
us to produce record amounts of our clean, consistent cannabis
using our unique aeroponic technology.
“In fact, we achieved a 28% increase in actual yield per plant
versus our previously reported estimated yields, and we expect this
to be sustainable. We estimate the additional yield alone could
boost revenue by at least $25 million annually once JWC2 is fully
operational.
“Initial sales from the JWC2 harvest began following the end of
the third quarter. However, right before the end of the quarter, we
secured the additional license from Health Canada to add 11,000 sf.
of flowering space, bringing the total to 22,000 sf. at JWC2. We
anticipate initial sales generated by this additional capacity to
begin in fiscal Q1 2020. Within the next couple of months, we
expect to receive a license to double this capacity again to a
total of 44,000 sf.
“In July, we received approval of a license amendment from
Health Canada to allow the sale of formulated cannabis oil from our
pilot JWC1 facility, thereby adding another valuable revenue
stream. More recently, we signed a purchase and supply agreement
with TerrAscend Corp (CSE: TER, OTCQX: TRSSF) to provide dry
cannabis flower and cannabis oils for sale on its online medical
sales platform. We also continue to be engaged in numerous
discussions with potential partners to expand the deployment of our
GrowthSTORM platform both domestically and abroad.
“As we complete the final quarter of our fiscal year, we will
continue to focus on building out production capacity and
distributing premium branded products for medical use and the
fast-growing Canadian recreational market. Our strong progress in
fiscal Q3, which has continued into the current quarter, has set
the stage for rapid revenue growth and profitability, and a
tremendous finish to fiscal 2019.”
Summary
Financial Results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3 2019 |
|
|
Q3 2018 |
|
Change % |
|
|
|
Q2 2019 |
|
Change % |
|
|
Revenues |
$ |
749,294 |
|
$ |
3,463 |
|
21,537 |
|
% |
$ |
566,315 |
|
32 |
|
% |
Operating expenses |
|
2,889,845 |
|
|
4,161,245 |
|
(31 |
) |
% |
|
3,235,685 |
|
(11 |
) |
% |
Loss from operations |
|
454,547 |
|
|
4,216,291 |
|
(89 |
) |
% |
|
3,434,883 |
|
(87 |
) |
% |
Net and comprehensive
loss |
|
433,908 |
|
|
4,648,038 |
|
(91 |
) |
% |
|
3,405,264 |
|
(87 |
) |
% |
Net and comprehensive loss per
share |
|
(0.01 |
) |
|
(0.06 |
) |
|
|
(0.04 |
) |
|
|
|
9M 2019 |
|
|
9M 2018 |
|
Change % |
|
|
Revenues |
$ |
1,835,985 |
|
$ |
3,463 |
|
52,917 |
|
% |
Operating expenses |
|
8,512,340 |
|
|
7,441,251 |
|
14 |
|
% |
Loss from operations |
|
6,265,364 |
|
|
6,440,025 |
|
(3 |
) |
% |
Net and comprehensive
loss |
|
6,164,463 |
|
|
8,064,865 |
|
(24 |
) |
% |
Net and comprehensive loss per
share |
|
(0.07 |
) |
|
(0.12 |
) |
|
|
|
6/30/2019 |
|
9/30/2018 |
Change % |
|
|
Cash and cash equivalents |
$ |
3,778,462 |
$ |
8,504,790 |
(56 |
) |
% |
Agricultural produce and
biological assets |
|
5,661,624 |
|
2,607,433 |
117 |
|
% |
Other working capital |
|
1,031,544 |
|
604,172 |
71 |
|
% |
Non-current assets |
|
17,293,655 |
|
5,475,701 |
216 |
|
% |
Other liabilities and
long-term debt |
|
6,945,912 |
|
3,411,615 |
104 |
|
% |
Shareholder’s equity |
|
15,681,818 |
|
19,639,466 |
(20 |
) |
% |
For the third fiscal quarter ended June 30, 2019, revenue
totaled a record $749,000, up 32% sequentially from $566,000, and
compared to $3,500 in the same year-ago quarter.
Revenue for the first nine months of fiscal 2019 increased to a
record $1.8 million from $3,500 in the same period last year.
Net and comprehensive loss was $434,000 or $(0.01) per share in
fiscal Q3 2019, improving 87% sequentially from $3.4 million or
$(0.04) per share, and improving 91% from $4.6 million or $(0.06)
per share in the year-ago quarter.
For the first nine months of the fiscal year, net and
comprehensive loss was $6.2 million or $(0.07) per share, improving
24% from $8.1 million or $(0.12) per share in the same year-ago
period.
Cash and equivalents at June 30, 2019 totaled $3.8 million,
compared to $2.3 million at March 31, 2019 and $18.0 million at
June 30, 2018. The decrease in cash is attributable to cash used in
operations.
Outlook
Inventories totaled approximately 458 kg of dried cannabis and
14 liters of formulated oil at the end of fiscal Q3 2019. These
products are in the process of being sold in the fourth quarter of
fiscal 2019.
The Company expects to soon begin selling cannabis products
through recreational channels, further developing customer demand,
as it continues scaling JWC2 towards full production capacity.
Given its expanding production capacity, the Company anticipates
revenue growth to accelerate over the next several quarters, with
modest increases in expenses. Management sees this trend resulting
in the Company achieving breakeven to positive net and
comprehensive income in Q4 2019 on an IFRS accounting basis
(factoring in the anticipated net increase in biological assets).
In Q1 2020, the Company expects to be revenue positive (revenue
exceeding expenses), along with positive net and comprehensive
income. By Q2 2020, the Company sees continued revenue growth
driving strong gross margins, positive cash flow, and net and
comprehensive income.
Additional Information
Additional details of the Company’s results for fiscal Q3 2019
are available in the interim financial statements and the
management’s discussion and analysis as filed on SEDAR at
www.sedar.com and available on the Company’s website at
www.jwc.ca.
Conference Call
JWC management will hold a conference call to discuss the third
quarter results later today, followed by a question and answer
period.
Date: Monday August 26, 2019Time: 5:00 p.m. Eastern time (2:00
p.m. Pacific time)Toll-free: 1-877-407-9208Toll/International:
1-201-493-6784Conference ID: 13694040
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization. If you have any difficulty connecting with the
conference call, please contact CMA at 1-949-432-7566.
A replay of the call will be available after 8:00 p.m. Eastern
time on the same day through September 9, 2019.
Toll-free replay number: 1-844-512-2921International replay
number: 1-412-317-6671Replay ID: 8692665
The conference call will also be webcast live and available for
replay here.
About James E. Wagner Cultivation
Corporation
Based in Kitchener, Ontario, James E. Wagner Cultivation
Corporation (JWC) is a licensed cannabis cultivator and
manufacturer focused on producing clean, consistent cannabis. The
Company’s proprietary Dual Droplet™ technology and GrowthSTORM™
aeroponic platform allows for unmatched consistency in quality and
potency. JWC began as a family-operated collective of patients and
growers, and has remained dedicated to producing the highest
quality and most consistent cannabis for medical and recreational
use. To learn more, visit www.jwc.ca.
Cautionary Note Regarding forward-looking
statementsThis press release contains statements including
forward-looking information for purposes of applicable securities
laws (“forward-looking statements”) about JWC and its business and
operations which include, among other things, statements regarding
increased harvests at either or both of the Company’s facilities,
increased distribution and sale of cannabis and cannabis oil by
JWC, expected sales of cannabis to the Canadian recreational
market, anticipated increases to profitability and revenue, the
expected receipt of licenses for additional flowering space at
JWC’s production facilities and the expected timing for receipt of
such licenses, the positive financial impact of the addition of new
flowering space at the Company’s facilities, potential partnerships
in relation to JWC’s GrowthSTORM platform and the financial growth
of the Company. The forward-looking statements can be identified by
the use of such words as “will”, “expected”, “approximately”,
“may”, “could”, “would” or similar words and phrases. These
forward-looking statements are based on the Company’s current
projections and expectations about future events and financial
trends that management believes might affect its financial
condition, results of operations, business strategy and financial
needs, and on certain assumptions and analysis made by the Company
in light of the experience and perception of historical trends,
current conditions and expected future developments and other
factors management believes are appropriate. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results to differ materially
from those implied in the forward-looking statements. For example,
risks include risks regarding the cannabis industry, economic
factors, the equity markets generally, building permit related
risks and risks associated with growth and competition as well as
the risks identified in the Company’s Filing Statement available
under the Company’s profile at www.sedar.com. Although JWC has
attempted to identify important factors that could result in actual
actions, unanticipated events may cause results to differ
materially from those described in forward-looking statements, and
there may be other factors that cause actions, events or results to
differ from those anticipated, estimated or intended. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release
and are based on current assumptions which management believes to
be reasonable. The Company disclaims any intention or obligation,
except to the extent required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Company ContactNathan WoodworthPresident &
CEO Tel (519) 594-0144 x421nathan@jwc.ca
Investor RelationsJonathan Leuchs,
CMA Tel (949) 432-7566 jwca@cma.team
James E. Wagner Cultivation Corporation |
|
Condensed Consolidated Interim Statement of Loss and Comprehensive
Loss (Unaudited) |
|
|
|
|
For the three months ending June 30, |
For the nine months ending June 30, |
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
|
|
|
|
|
Revenue |
|
|
|
|
Wholesale |
|
638,179 |
|
|
- |
|
|
1,615,468 |
|
|
- |
|
Direct to patient |
|
111,115 |
|
|
3,463 |
|
|
220,517 |
|
|
3,463 |
|
|
|
749,294 |
|
|
3,463 |
|
|
1,835,985 |
|
|
3,463 |
|
Cost of
sales |
|
738,926 |
|
|
2,334 |
|
|
3,041,747 |
|
|
2,334 |
|
Gross profit before the undernoted |
|
10,368 |
|
|
1,129 |
|
|
(1,205,762 |
) |
|
1,129 |
|
Changes in fair value of biological assets |
|
2,424,930 |
|
|
(56,175 |
) |
|
3,452,738 |
|
|
800,097 |
|
|
|
2,435,298 |
|
|
(55,046 |
) |
|
2,246,976 |
|
|
801,226 |
|
|
|
|
|
|
Expenses |
|
|
|
|
Wages and benefits |
|
1,003,329 |
|
|
321,004 |
|
|
2,847,981 |
|
|
982,209 |
|
Rent |
|
630,176 |
|
|
698,471 |
|
|
2,031,999 |
|
|
1,475,231 |
|
Professional fees |
|
131,895 |
|
|
596,186 |
|
|
788,653 |
|
|
1,797,402 |
|
Office and administration |
|
264,471 |
|
|
223,422 |
|
|
618,468 |
|
|
298,668 |
|
Advertising and promotion |
|
143,791 |
|
|
123,675 |
|
|
433,007 |
|
|
204,368 |
|
Utilities |
|
137,506 |
|
|
99,018 |
|
|
425,084 |
|
|
170,035 |
|
Depreciation |
|
325,479 |
|
|
58,826 |
|
|
579,199 |
|
|
177,031 |
|
Royalty expense |
|
116,948 |
|
|
117,677 |
|
|
351,515 |
|
|
120,263 |
|
Banking and service fees |
|
9,506 |
|
|
1,759 |
|
|
155,005 |
|
|
6,417 |
|
Interest expense |
|
46,073 |
|
|
41,220 |
|
|
100,028 |
|
|
289,140 |
|
Repairs and maintenance |
|
62,876 |
|
|
53,925 |
|
|
115,546 |
|
|
89,052 |
|
Memberships and licenses |
|
17,795 |
|
|
30,338 |
|
|
65,855 |
|
|
35,711 |
|
Listing expense |
|
- |
|
|
1,795,724 |
|
|
- |
|
|
1,795,724 |
|
|
|
2,889,845 |
|
|
4,161,245 |
|
|
8,512,340 |
|
|
7,441,251 |
|
|
|
|
|
|
Loss from
operations |
|
(454,547 |
) |
|
(4,216,291 |
) |
|
(6,265,364 |
) |
|
(6,440,025 |
) |
|
|
|
|
|
Fair value change in
contingently issuable shares |
|
- |
|
|
(462,657 |
) |
|
- |
|
|
(1,482,337 |
) |
Interest and other
revenue |
|
20,639 |
|
|
30,910 |
|
|
100,901 |
|
|
57,496 |
|
|
|
20,639 |
|
|
(431,747 |
) |
|
100,901 |
|
|
(1,424,840 |
) |
|
|
|
|
|
Loss and comprehensive loss |
$ |
(433,908 |
) |
$ |
(4,648,038 |
) |
$ |
(6,164,463 |
) |
$ |
(8,064,865 |
) |
Loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and Diluted |
$ |
(0.01 |
) |
$ |
(0.06 |
) |
$ |
(0.07 |
) |
$ |
(0.12 |
) |
James E. Wagner Cultivation Corporation |
|
Condensed Consolidated Interim Statement of Financial Position
(Unaudited) |
|
|
|
|
|
|
|
|
|
June 30, 2019 |
|
|
September 30, 2018 |
|
Assets |
|
|
|
|
|
|
Current |
|
|
|
|
|
|
Cash and cash equivalents |
$ |
3,778,462 |
|
$ |
8,504,790 |
|
Short term investments |
|
|
|
6,017,153 |
|
Funds in trust |
|
- |
|
|
140,165 |
|
Accounts Receivable |
|
736,335 |
|
|
120,255 |
|
Government remittances recoverable |
|
295,209 |
|
|
343,752 |
|
Inventory |
|
2,188,569 |
|
|
1,532,604 |
|
Biological assets |
|
3,473,055 |
|
|
1,074,829 |
|
Prepaid expenses and deposits |
|
888,506 |
|
|
943,299 |
|
|
|
11,360,136 |
|
|
18,676,847 |
|
|
|
|
|
|
Capital assets |
|
17,173,623 |
|
|
5,331,068 |
|
Intangible assets |
|
120,032 |
|
|
144,633 |
|
|
|
17,293,655 |
|
|
5,475,701 |
|
|
|
|
|
|
|
|
|
$ |
28,653,791 |
|
$ |
24,152,548 |
|
|
|
|
Assets Liabilities and Shareholders’ Equity
(Deficiency) |
|
|
Current |
|
|
|
|
Accounts payable and accrued liabilities |
$ |
1,124,986 |
|
$ |
1,098,212 |
|
Current portion of long-term debt |
|
4,901,075 |
|
|
3,253 |
|
|
|
6,026,061 |
|
|
1,101,465 |
|
|
|
|
|
|
Long-term debt |
|
3,003,385 |
|
|
5,528 |
|
Royalty liability |
|
2,495,656 |
|
|
2,489,102 |
|
Lease inducement |
|
1,446,871 |
|
|
916,985 |
|
|
|
6,945,912 |
|
|
3,411,615 |
|
|
|
|
|
|
Shareholders’ equity |
|
|
|
|
Share capital |
|
33,198,306 |
|
|
30,446,310 |
|
Contributed surplus |
|
3,655,603 |
|
|
4,200,786 |
|
Retained earnings (deficit) |
|
(21,172,091 |
) |
|
(15,007,628 |
) |
|
|
15,681,818 |
|
|
19,639,468 |
|
|
|
|
|
|
|
$ |
28,653,791 |
|
$ |
24,152,548 |
|
Please see the accompanying notes, which are an integral part of
these condensed interim financial statements, that are available in
the interim financial statements and the management’s discussion
and analysis as filed on SEDAR at www.sedar.com and available on
the company’s website at www.jwc.ca.
James E Wagner Cultivation (TSXV:JWCA)
Historical Stock Chart
From Nov 2024 to Dec 2024
James E Wagner Cultivation (TSXV:JWCA)
Historical Stock Chart
From Dec 2023 to Dec 2024